XML 97 R87.htm IDEA: XBRL DOCUMENT
v3.23.2

LEGAL PROCEEDINGS - Intellectual Property (Details) |  |  |  |  |  | 1 Months Ended | 6 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Aug. 03, 2023 defendant | Jul. 21, 2022 | Feb. 02, 2022 | Sep. 10, 2021 | Mar. 26, 2020 | Jan. 31, 2023 | Apr. 30, 2021 | Mar. 31, 2021 defendant proceeding | Jun. 30, 2023 defendant lawsuit
Norwich Pharmaceuticals Inc. Litigation |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Stay of approval, period |  |  |  |  | 30 months |  |  |  |
Taro Pharmaceuticals Inc. Litigation |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Stay of approval, period |  | 30 months |  |  |  |  |  |  |
MSN Laboratories Private Ltd. Litigation |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Stay of approval, period |  |  |  |  |  |  | 30 months |  |
Aurobindo Pharma Limited Litigation |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Stay of approval, period |  |  |  |  |  | 30 months |  |  |
PreserVision® AREDS Patent Litigation | Bausch + Lomb |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of defendants |  |  |  |  |  |  |  | 19 |
Number of proceedings | proceeding |  |  |  |  |  |  |  | 16 |
PreserVision® AREDS Patent Litigation | Settled Litigation | Bausch + Lomb |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of defendants |  |  |  |  |  |  |  |  | 12
PreserVision® AREDS Patent Litigation | Default Judgement | Bausch + Lomb |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of defendants |  |  |  |  |  |  |  |  | 2
PreserVision® AREDS Patent Litigation | Pending Litigation | Bausch + Lomb | Subsequent Event |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of defendants | 2 |  |  |  |  |  |  |  |
Lumify Paragraph I V Proceedings Slayback ANDA Litigation |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Stay of approval, period |  |  |  | 30 months |  |  |  |  |
Lumify Paragraph I V Proceedings Lupin ANDA Litigation |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Stay of approval, period |  |  | 30 months |  |  |  |  |  |
Apotex Inc. Litigation | Canada | Pending Litigation |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of lawsuits pending | lawsuit |  |  |  |  |  |  |  |  | 1

X
- Definition Gain Contingency, Number Of Defendants + References No definition available. + Details
Name: | bhc_GainContingencyNumberOfDefendants
Namespace Prefix: | bhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Number Of Proceedings + References No definition available. + Details
Name: | bhc_GainContingencyNumberOfProceedings
Namespace Prefix: | bhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Stay Of Approval, Period + References No definition available. + Details
Name: | bhc_GainContingencyStayOfApprovalPeriod
Namespace Prefix: | bhc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity has allegedly infringed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1 + Details
Name: | us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_AurobindoPharmaLimitedLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CA
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |